Commonwealth Equity Services’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,884
| Closed | -$275K | – | 4262 |
|
|
2025
Q1 | $275K | Sell |
3,884
-1,123
| -22% | -$75.6K | ﹤0.01% | 3578 |
|
|
2024
Q4 | $329K | Sell |
5,007
-1,318
| -21% | -$88.3K | ﹤0.01% | 3331 |
|
|
2024
Q3 | $445K | Sell |
6,325
-907
| -13% | -$75.8K | ﹤0.01% | 2987 |
|
|
2024
Q2 | $595K | Sell |
7,232
-58
| -0.8% | -$4.83K | ﹤0.01% | 2688 |
|
|
2024
Q1 | $637K | Buy |
7,290
+454
| +7% | +$40.6K | ﹤0.01% | 2608 |
|
|
2023
Q4 | $659K | Sell |
6,836
-577
| -8% | -$51K | ﹤0.01% | 2486 |
|
|
2023
Q3 | $656K | Buy |
7,413
+568
| +8% | +$50.5K | ﹤0.01% | 2365 |
|
|
2023
Q2 | $593K | Buy |
6,845
+660
| +11% | +$62.1K | ﹤0.01% | 2479 |
|
|
2023
Q1 | $601 | Buy |
6,185
+731
| +13% | +$75.8K | ﹤0.01% | 2390 |
|
|
2022
Q4 | $564K | Buy |
5,454
+110
| +2% | +$10.3K | ﹤0.01% | 2372 |
|
|
2022
Q3 | $453K | Sell |
5,344
-393
| -7% | -$35K | ﹤0.01% | 2491 |
|
|
2022
Q2 | $475K | Sell |
5,737
-553
| -9% | -$44K | ﹤0.01% | 2444 |
|
|
2022
Q1 | $484K | Sell |
6,290
-24,088
| -79% | -$2.02M | ﹤0.01% | 2554 |
|
|
2021
Q4 | $2.68M | Sell |
30,378
-1,021
| -3% | -$84.2K | 0.01% | 1298 |
|
|
2021
Q3 | $2.43M | Sell |
31,399
-227
| -0.7% | -$17.9K | 0.01% | 1312 |
|
|
2021
Q2 | $2.64M | Buy |
31,626
+156
| +0.5% | +$12.4K | 0.01% | 1245 |
|
|
2021
Q1 | $2.38M | Buy |
31,470
+2,615
| +9% | +$214K | 0.01% | 1211 |
|
|
2020
Q4 | $2.53M | Buy |
28,855
+26,107
| +950% | +$2.07M | 0.01% | 1093 |
|
|
2020
Q3 | $209K | Sell |
2,748
-1,036
| -27% | -$105K | ﹤0.01% | 2680 |
|
|
2020
Q2 | $466K | Buy |
3,784
+333
| +10% | +$33.1K | ﹤0.01% | 1929 |
|
|
2020
Q1 | $291K | Buy |
3,451
+415
| +14% | +$35.8K | ﹤0.01% | 2089 |
|
|
2019
Q4 | $256K | Sell |
3,036
-6,410
| -68% | -$484K | ﹤0.01% | 2433 |
|
|
2019
Q3 | $636K | Sell |
9,446
-2,081
| -18% | -$160K | ﹤0.01% | 1665 |
|
|
2019
Q2 | $987K | Buy |
11,527
+383
| +3% | +$32.8K | ﹤0.01% | 1352 |
|
|
2019
Q1 | $989K | Buy |
11,144
+1,424
| +15% | +$132K | ﹤0.01% | 1303 |
|
|
2018
Q4 | $827K | Buy |
9,720
+1,418
| +17% | +$135K | ﹤0.01% | 1323 |
|
|
2018
Q3 | $805K | Buy |
8,302
+1,078
| +15% | +$108K | ﹤0.01% | 1442 |
|
|
2018
Q2 | $681K | Buy |
7,224
+367
| +5% | +$32.1K | ﹤0.01% | 1534 |
|
|
2018
Q1 | $555K | Buy |
6,857
+1,470
| +27% | +$126K | ﹤0.01% | 1648 |
|
|
2017
Q4 | $480K | Sell |
5,387
-1,071
| -17% | -$93.1K | ﹤0.01% | 1727 |
|
|
2017
Q3 | $601K | Sell |
6,458
-57
| -0.9% | -$5.04K | ﹤0.01% | 1496 |
|
|
2017
Q2 | $592K | Buy |
6,515
+840
| +15% | +$76.4K | ﹤0.01% | 1454 |
|
|
2017
Q1 | $498K | Buy |
5,675
+198
| +4% | +$17.6K | ﹤0.01% | 1507 |
|
|
2016
Q4 | $454K | Buy |
+5,477
| New | +$471K | ﹤0.01% | 1459 |
|
|
2016
Q1 | – | Sell |
-3,107
| Closed | -$325K | – | 2216 |
|
|
2015
Q4 | $325K | Buy |
+3,107
| New | +$324K | ﹤0.01% | 1551 |
|
|
2015
Q3 | – | Sell |
-4,103
| Closed | -$561K | – | 2152 |
|
|
2015
Q2 | $561K | Sell |
4,103
-6,003
| -59% | -$744K | 0.01% | 1268 |
|
|
2015
Q1 | $1.26M | Buy |
10,106
+5,299
| +110% | +$561K | 0.01% | 832 |
|
|
2014
Q4 | $435K | Buy |
4,807
+23
| +0.5% | +$1.91K | ﹤0.01% | 1356 |
|
|
2014
Q3 | $345K | Sell |
4,784
-521
| -10% | -$34.2K | ﹤0.01% | 1461 |
|
|
2014
Q2 | $330K | Buy |
5,305
+12
| +0.2% | +$725 | ﹤0.01% | 1485 |
|
|
2014
Q1 | $361K | Sell |
5,293
-479
| -8% | -$35.3K | 0.01% | 1361 |
|
|
2013
Q4 | $406K | Buy |
+5,772
| New | +$392K | 0.01% | 1257 |
|
Other funds holding BMRN
Commonwealth Equity Services's BMRN Position: Q2 2025 in Review
Commonwealth Equity Services sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 3,884 shares — an estimated $275K sold.
Commonwealth Equity Services first reported a position in BMRN in Q4 2013 and held it in 42 quarters. The position peaked at $2.68M in Q4 2021. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.
- Commonwealth Equity Services reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Commonwealth Equity Services sold 3,884 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $275K.
- Commonwealth Equity Services first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 42 quarters.
- Commonwealth Equity Services's BioMarin Pharmaceuticals position peaked at $2.68M in Q4 2021.
- 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.
Based on Commonwealth Equity Services's 13F filing for Q2 2025, filed 6 Aug 2025.